Clinical Trial Update: Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial compared paclitaxel alone to paclitaxel plus sorafenib in second- or third-line treatment of metastatic breast cancer; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nexavar (Sorafenib)
• Taxol (paclitaxel)

Snippet

Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED